Detailed Narrative
Segment Reorganization and Enhanced Disclosure
Starting Q1 FY23, Jubilant Pharmova reorganized its reporting into four segments: Specialty Pharmaceuticals, CDMO Sterile Injectables, Generics, and CRDMO. This move provides investors with granular EBITDA data for each business line, revealing the stark contrast between the profitable Specialty and CDMO segments and the loss-making Generics business. Management emphasized that this transparency will help track the turnaround progress of individual units.
Generics Segment Faces Perfect Storm
The Generics business reported a revenue of ₹178 Crore, down 59% YoY, and a negative EBITDA of ₹70 Crore. This was driven by a combination of US pricing pressure, a sharp fall in Sartan prices as more players entered the market, and the ongoing Import Alert at the Roorkee plant. Management expects a turnaround by the end of FY23, contingent on a favorable USFDA outcome and shifting production to other CMO sites.
Radiopharmaceuticals Recovery and Specialty Growth
Specialty Pharmaceuticals revenue grew to ₹722 Crore, led by a recovery in Radiopharmaceuticals as pandemic impacts eased. Ruby-Fill installations reached record quarterly highs, and the Radiopharmacy turnaround plan is reportedly on track for FY24 breakeven. The Allergy business also continued to perform strongly, operating at volumes higher than pre-COVID levels.
CDMO Sterile Injectables Normalization
Revenue in the CDMO Sterile Injectables segment fell to ₹263 Crore from ₹373 Crore YoY, primarily due to the reduction in COVID-related deals from ₹220 Crore to ₹70 Crore. Despite the drop, the segment maintains healthy margins (approx. 50% EBITDA margin). Management is investing heavily in this segment, with a significant portion of the ₹700-750 Crore FY23 Capex dedicated to expanding capacity in Spokane and Montreal.
CRDMO Segment Emerges as Growth Driver
The newly formed CRDMO segment, combining Drug Discovery Services and CDMO-API, reported 45% YoY revenue growth to ₹280 Crore. Drug Discovery Services alone grew 34% YoY, driven by robust demand from biotech companies. Management plans to add 20-25% capacity in this segment by FY24 to sustain a 25% annual growth rate, supported by the expansion of the Greater Noida facility.